Severine Vermeire

Summary

Affiliation: Katholieke Universiteit Leuven
Country: Belgium

Publications

  1. doi request reprint Role of biomarkers in the diagnosis of inflammatory bowel disease
    Severine Vermeire
    University Hospital Leuven, Department of Gastroenterology, Herestraat 49, 3000 Leuven, Belgium 32 16 34 42 25 32 16 34 43 99
    Expert Opin Med Diagn 1:481-8. 2007
  2. doi request reprint Towards a novel molecular classification of IBD
    Severine Vermeire
    Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Dig Dis 30:425-7. 2012
  3. doi request reprint Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis
    L Marquez
    Department of Gastroenterology, Gasthuisberg Hospital, KU Leuven, Belgium
    Gut 61:528-34. 2012
  4. ncbi request reprint Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD
    Severine Vermeire
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Gastroenterology 129:1845-53. 2005
  5. ncbi request reprint Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease
    S Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Aliment Pharmacol Ther 24:2-10. 2006
  6. ncbi request reprint The use of immunosuppressive drugs in IBD: RAND or random choice?
    S Vermeire
    University Hospital Gasthuisberg, Division of Gastroenterology, Herestraat 49, 3000 Leuven, Belgium
    Dig Liver Dis 37:391-3. 2005
  7. ncbi request reprint Serum sickness, encephalitis and other complications of anti-cytokine therapy
    Severine Vermeire
    University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
    Best Pract Res Clin Gastroenterol 23:101-12. 2009
  8. ncbi request reprint Current status of genetics research in inflammatory bowel disease
    S Vermeire
    University Hospital Gasthuisberg Leuven, Division of Gastroenterology Herestraat, Leuven 49 3000, Belgium
    Genes Immun 6:637-45. 2005
  9. ncbi request reprint The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases
    Severine Vermeire
    Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Nat Clin Pract Gastroenterol Hepatol 2:580-6. 2005
  10. doi request reprint (Auto)antibodies in inflammatory bowel diseases
    Severine Vermeire
    Department of Gastroenterology, University Hospitals Leuven Belgium, UZ Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Gastroenterol Clin North Am 37:429-38, vii. 2008

Detail Information

Publications100

  1. doi request reprint Role of biomarkers in the diagnosis of inflammatory bowel disease
    Severine Vermeire
    University Hospital Leuven, Department of Gastroenterology, Herestraat 49, 3000 Leuven, Belgium 32 16 34 42 25 32 16 34 43 99
    Expert Opin Med Diagn 1:481-8. 2007
    ..Nevertheless, these markers are often negative in this setting. The interest in antimicrobial and antiglycan antibodies has recently been increased as they have shown to act as surrogate markers of complicated aggressive disease...
  2. doi request reprint Towards a novel molecular classification of IBD
    Severine Vermeire
    Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Dig Dis 30:425-7. 2012
    ..Only then could the value of molecular markers to predict the speed of progression be fully explored in prospective studies...
  3. doi request reprint Effects of haptoglobin polymorphisms and deficiency on susceptibility to inflammatory bowel disease and on severity of murine colitis
    L Marquez
    Department of Gastroenterology, Gasthuisberg Hospital, KU Leuven, Belgium
    Gut 61:528-34. 2012
    ..Its gene (16q22) harbours a common polymorphism with two different alleles: Hp1 and Hp2. Genotype Hp22 has been shown to be over-represented in different immune diseases. Results in Crohn's disease (CD) are contradictory...
  4. ncbi request reprint Association of organic cation transporter risk haplotype with perianal penetrating Crohn's disease but not with susceptibility to IBD
    Severine Vermeire
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Gastroenterology 129:1845-53. 2005
    ..We studied mutation prevalence, assessed phenotypic expression, and performed conditional analysis to examine evidence for gene-gene interactions...
  5. ncbi request reprint Review article: genetic susceptibility and application of genetic testing in clinical management of inflammatory bowel disease
    S Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Aliment Pharmacol Ther 24:2-10. 2006
    ..In the future, it is anticipated that genetic markers will be implemented in an integrated molecular diagnostic and prognostic approach to managing our patients...
  6. ncbi request reprint The use of immunosuppressive drugs in IBD: RAND or random choice?
    S Vermeire
    University Hospital Gasthuisberg, Division of Gastroenterology, Herestraat 49, 3000 Leuven, Belgium
    Dig Liver Dis 37:391-3. 2005
  7. ncbi request reprint Serum sickness, encephalitis and other complications of anti-cytokine therapy
    Severine Vermeire
    University Hospitals Leuven, Herestraat 49, 3000 Leuven, Belgium
    Best Pract Res Clin Gastroenterol 23:101-12. 2009
    ..We discuss the safety aspects of the biological agents in this chapter and, where available, give ways to prevent and/or treat them...
  8. ncbi request reprint Current status of genetics research in inflammatory bowel disease
    S Vermeire
    University Hospital Gasthuisberg Leuven, Division of Gastroenterology Herestraat, Leuven 49 3000, Belgium
    Genes Immun 6:637-45. 2005
    ..Overall, it is anticipated that genetic markers in the future will be implemented in an integrated molecular diagnostic and prognostic approach of our patients...
  9. ncbi request reprint The role of C-reactive protein as an inflammatory marker in gastrointestinal diseases
    Severine Vermeire
    Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Nat Clin Pract Gastroenterol Hepatol 2:580-6. 2005
    ..Until there are more data, the use of CRP and of other biomarkers should be seen as an additional tool that aids clinical observation and physical examination, but that cannot replace it...
  10. doi request reprint (Auto)antibodies in inflammatory bowel diseases
    Severine Vermeire
    Department of Gastroenterology, University Hospitals Leuven Belgium, UZ Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Gastroenterol Clin North Am 37:429-38, vii. 2008
    ..However, currently, they have no place in the diagnostic work up. Their real promise may lie in their use as surrogate markers of complicated aggressive disease as shown in various retrospective studies, but prospective data are lacking...
  11. pmc Laboratory markers in IBD: useful, magic, or unnecessary toys?
    S Vermeire
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Gut 55:426-31. 2006
    ..They are however not magic and until more data become available, the use of CRP and other laboratory markers should be seen as an additive tool to clinical observation and physical examination rather than a replacement...
  12. ncbi request reprint The changing face of treatment for Crohn's disease
    S Vermeire
    Department of Medicine, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Br J Surg 93:385-6. 2006
  13. ncbi request reprint Perianal Crohn's disease: classification and clinical evaluation
    S Vermeire
    Division of Gastroenterology, University of Leuven, Herestraat 49, 3000 Leuven, Belgium
    Dig Liver Dis 39:959-62. 2007
    ..This review analyses and discusses current classifications of any perianal form of Crohn's disease...
  14. ncbi request reprint Review article: Altering the natural history of Crohn's disease--evidence for and against current therapies
    S Vermeire
    Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium
    Aliment Pharmacol Ther 25:3-12. 2007
    ..Major advances in treatment options over the past years have made our treatment goals more ambitious and modification of the natural course has become the ultimate endpoint...
  15. ncbi request reprint Correlation between the Crohn's disease activity and Harvey-Bradshaw indices in assessing Crohn's disease severity
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Clin Gastroenterol Hepatol 8:357-63. 2010
    ..We investigated whether a simpler tool, the Harvey-Bradshaw Index, was equally effective in assessing disease severity...
  16. doi request reprint The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 60:1068-75. 2011
    ..This first-in-human study of a monoclonal antibody to MAdCAM, PF-00547,659, aimed to explore the safety and preliminary efficacy of this gut-specific mechanism in ulcerative colitis...
  17. pmc Role of genetics in prediction of disease course and response to therapy
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    World J Gastroenterol 16:2609-15. 2010
    ..Nevertheless, the importance and necessity of pharmacogenetic studies will increase further as more therapeutic classes are being developed...
  18. doi request reprint To what extent are genetics clinically useful?
    Severine Vermeire
    Gastroenterology Department, University Hospitals Leuven, Leuven, Belgium
    Best Pract Res Clin Gastroenterol 25:S8-14. 2011
    ..Efforts to predict disease course and response to therapy have shown interesting results...
  19. doi request reprint Inflammatory bowel disease and colitis: new concepts from the bench and the clinic
    Severine Vermeire
    Department of Gastroenterology, University Hospitals Leuven, Leuven, Belgium
    Curr Opin Gastroenterol 27:32-7. 2011
    ..The previous 18 months have shown important progress in unravelling the causes of inflammatory bowel disease (IBD) and in improving its management for the patients...
  20. ncbi request reprint NOD2/CARD15: relevance in clinical practice
    Severine Vermeire
    Gastroenterology Unit, University Hospital Gasthuisberg Leuven, Herestraat 49, 3000 Leuven, Belgium
    Best Pract Res Clin Gastroenterol 18:569-75. 2004
    ..Finally, screening unaffected relatives of CD patients is not recommended until preventive strategies are available...
  21. ncbi request reprint The value of myenteric plexitis to predict early postoperative Crohn's disease recurrence
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 130:1595-606. 2006
    ..Unequivocal histologic markers predicting recurrence have not been identified. We assessed the predictive value of neural lesions for early endoscopic CD recurrence and long-term reintervention risk...
  22. ncbi request reprint Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a randomized trial
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 134:1861-8. 2008
    ..We aimed to study the influence of immunosuppressives discontinuation in patients in remission with combination therapy in an open-label, randomized, controlled trial...
  23. doi request reprint Clustering of (auto)immune diseases with early-onset and complicated inflammatory bowel disease
    Mirjam Bueno de Mesquita
    Department of Paediatric Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, 3000 Leuven, Belgium
    Eur J Pediatr 168:575-83. 2009
    ..6%, respectively, p<0.0001) and more often had concomitant immune-mediated diseases and a trend for more seroreactivity towards ASCA...
  24. pmc Mutations in pattern recognition receptor genes modulate seroreactivity to microbial antigens in patients with inflammatory bowel disease
    Liesbet Henckaerts
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 56:1536-42. 2007
    ....
  25. doi request reprint Mucosal gene expression of cell adhesion molecules, chemokines, and chemokine receptors in patients with inflammatory bowel disease before and after infliximab treatment
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 106:748-61. 2011
    ..This migration is regulated by cell adhesion molecules (CAMs), and selective antimigration therapies have been developed. This study investigated the effect of infliximab therapy on the mucosal gene expression of CAMs in IBD...
  26. pmc Unique gene expression and MR T2 relaxometry patterns define chronic murine dextran sodium sulphate colitis as a model for connective tissue changes in human Crohn's disease
    Christine Breynaert
    Translational Research Center for Gastrointestinal Disorders TARGID, Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
    PLoS ONE 8:e68876. 2013
    ..The aim of this study was to investigate changes in connective tissue in a chronic murine model resulting from repeated cycles of dextran sodium sulphate (DSS) ingestion, to mimic the relapsing nature of the human disease...
  27. ncbi request reprint Pancreatic autoantibodies in inflammatory bowel disease
    Sofie Joossens
    Department of Gastroenterology, University Hospital Gasthuisberg, Katholieke Universiteit Leuven, Leuven, Belgium
    Inflamm Bowel Dis 10:771-7. 2004
    ..We studied PABs in patients with inflammatory bowel disease (IBD), unaffected family members, and control subjects...
  28. ncbi request reprint Transmission of CARD15 (NOD2) variants within families of patients with inflammatory bowel disease
    Nele Esters
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 99:299-305. 2004
    ..Since nothing is known about the transmission of these variants within families, this was the subject of our study in Flemish patients with inflammatory bowel disease (IBD) and their healthy relatives...
  29. ncbi request reprint Anxiety is associated with impaired tolerance of colonoscopy preparation in inflammatory bowel disease and controls
    Talat Bessissow
    Department of Gastroenterology, University Hospital Leuven, Leuven, Belgium Department of Gastroenterology, Royal Victoria Hospital, McGill University Health Center, Montreal, Canada Electronic address
    J Crohns Colitis 7:e580-7. 2013
    ..Pain and nausea are often reported during bowel cleansing (BC) for ileocolonoscopy (IC). We aimed to explore putative mechanisms associated with impaired tolerance to BC...
  30. ncbi request reprint Genetic variants in autophagy-related genes and granuloma formation in a cohort of surgically treated Crohn's disease patients
    Marko Brinar
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    J Crohns Colitis 6:43-50. 2012
    ..Genetic variants in autophagy genes IRGM and ATG16L1 have been associated with susceptibility to Crohn's disease. We therefore investigated whether variants in autophagy genes contribute to granuloma formation...
  31. doi request reprint Immunosuppression in inflammatory bowel disease: traditional, biological or both?
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Curr Opin Gastroenterol 25:323-8. 2009
    ..To focus on the emerging clinical evidence for the use of traditional immunosuppressives and biologicals in the treatment of inflammatory bowel disease...
  32. doi request reprint Cystic fibrosis transmembrane conductance regulator gene polymorphisms in patients with primary sclerosing cholangitis
    Liesbet Henckaerts
    Department of Gastroenterology, University Hospital Gasthuisberg, Catholic University of Leuven, Herestraat 49, B 3000 Leuven, Belgium
    J Hepatol 50:150-7. 2009
    ..The histological features in the liver of PSC patients are similar to those observed in cystic fibrosis (CF). Our aim was to study whether variants in the CFTR gene are associated with the occurrence and/or evolution of PSC...
  33. doi request reprint Mucosal healing predicts sustained clinical remission in patients with early-stage Crohn's disease
    Filip Baert
    Department of Gastroenterology, H Hartziekenhuis Roeselare Menen vzw, Roeselare, Belgium
    Gastroenterology 138:463-8; quiz e10-1. 2010
    ..Few prospective data are available to support the clinical relevance of mucosal healing in patients with Crohn's disease. This study examined whether complete healing, determined by endoscopy, predicts a better outcome in Crohn's disease...
  34. ncbi request reprint Predictive value of epithelial gene expression profiles for response to infliximab in Crohn's disease
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:2090-8. 2010
    ..However, a subset of patients shows incomplete or no response to this agent. In this study we investigated whether we could identify a mucosal gene panel to predict (non)response to IFX in CD...
  35. pmc Mucosal gene expression of antimicrobial peptides in inflammatory bowel disease before and after first infliximab treatment
    Ingrid Arijs
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    PLoS ONE 4:e7984. 2009
    ..We investigated the impact of anti-inflammatory therapy with infliximab on the mucosal gene expression of AMPs in IBD...
  36. ncbi request reprint Toll-like receptor-1, -2, and -6 polymorphisms influence disease extension in inflammatory bowel diseases
    Marie Pierik
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:1-8. 2006
    ..This is underscored by the finding of the association between CARD15 variants and Crohn's disease (CD) and D299G in Toll-like receptor (TLR) 4 and IBD. Our aims were to study nonsynonymous polymorphisms in other TLR genes in IBD...
  37. ncbi request reprint Long-term outcome of treatment with intravenous cyclosporin in patients with severe ulcerative colitis
    Joris Arts
    Department of Internal Medicine, University Hospital, Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Inflamm Bowel Dis 10:73-8. 2004
    ..It remains unclear if this treatment affects the course of the disease in the long run. We investigated the long-term efficacy and safety in 86 patients with ulcerative colitis treated with i.v. CSA at our center...
  38. ncbi request reprint Demographic and clinical parameters influencing the short-term outcome of anti-tumor necrosis factor (infliximab) treatment in Crohn's disease
    Severine Vermeire
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 97:2357-63. 2002
    ..The aim of this study was to assess whether demographic or clinical parameters influence short-term response to infliximab...
  39. doi request reprint Prognostic value of serologic and histologic markers on clinical relapse in ulcerative colitis patients with mucosal healing
    Talat Bessissow
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Am J Gastroenterol 107:1684-92. 2012
    ..We aimed to investigate the predictive role of serologic and histologic markers on disease relapse in UC patients with endoscopically inactive disease...
  40. pmc New serological markers in inflammatory bowel disease are associated with complicated disease behaviour
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    Gut 56:1394-403. 2007
    ....
  41. pmc Treatment of severe steroid refractory ulcerative colitis
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Herestraat 49, Leuven, Belgium
    World J Gastroenterol 14:5508-11. 2008
    ..Therefore, patients not responding to these agents within 5-7 d should be considered for colectomy and responders should be closely monitored for infections...
  42. pmc Effectiveness of concomitant immunosuppressive therapy in suppressing the formation of antibodies to infliximab in Crohn's disease
    Severine Vermeire
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 56:1226-31. 2007
    ..Concomitant use of immunosuppressives (IS) reduces the risk of ATI formation...
  43. ncbi request reprint The role of vascular endothelial growth factor (VEGF) in inflammatory bowel disease
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:870-8. 2006
    ..Moreover, serum VEGF (sVEGF) levels are increased in IBD and correlate with disease activity. Both VEGF expression and sVEGF levels may be influenced by VEGF gene polymorphisms...
  44. doi request reprint Levels of C-reactive protein are associated with response to infliximab therapy in patients with Crohn's disease
    Matthias Jürgens
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Clin Gastroenterol Hepatol 9:421-7.e1. 2011
    ..C-reactive protein (CRP) is a marker used to identify and follow individuals with CD. We analyzed changes in levels of CRP in a large cohort of patients with CD undergoing treatment with infliximab...
  45. ncbi request reprint Mucosal healing predicts long-term outcome of maintenance therapy with infliximab in Crohn's disease
    Fabian Schnitzler
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 15:1295-301. 2009
    ..Infliximab (IFX) treatment induces mucosal healing (MH) in patients with Crohn's disease (CD) but the impact of MH on the long-term outcome of IFX treatment in CD is still debated...
  46. ncbi request reprint Efficacy of infliximab in refractory pouchitis and Crohn's disease-related complications of the pouch: a Belgian case series
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:243-9. 2010
    ..In case reports, thiopurine analogs and infliximab (IFX) have been proposed as effective therapy in this setting. We analyzed the long-term efficacy of IFX in Belgian patients with refractory pouch complications...
  47. doi request reprint Correlation between the endoscopic and histologic score in assessing the activity of ulcerative colitis
    Bart Lemmens
    Translational Cell and Tissue Research, Department of Imaging and Pathology, University Hospital KU Leuven, Leuven, Belgium
    Inflamm Bowel Dis 19:1194-201. 2013
    ..It is still unknown how well they correlate and whether scoring both endoscopy and histology better reflects the true disease activity than each of the methods separately...
  48. doi request reprint Decreased mucosal sulfide detoxification is related to an impaired butyrate oxidation in ulcerative colitis
    Vicky De Preter
    Translational Research Center for Gastrointestinal Disorders TARGID and Leuven Food Science and Nutrition Research Centre LFoRCe, University Hospital Gasthuisberg, KULeuven, Leuven, Belgium
    Inflamm Bowel Dis 18:2371-80. 2012
    ..In this study we measured colonic mucosal TST enzyme activity and gene expression in UC and controls. In addition, the influence of sulfides on butyrate oxidation was evaluated...
  49. ncbi request reprint C-reactive protein as a marker for inflammatory bowel disease
    Severine Vermeire
    Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 10:661-5. 2004
    ..However, whether we need to include CRP as an inclusion criterion for future trials with biologicals is still a matter of debate...
  50. ncbi request reprint Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease
    Konstantinos Karmiris
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gastroenterology 137:1628-40. 2009
    ....
  51. ncbi request reprint The value of serologic markers in indeterminate colitis: a prospective follow-up study
    Sofie Joossens
    Gastroenterology Unit, Department of Pathology, U Z Gasthuisberg, Leuven, Belgium
    Gastroenterology 122:1242-7. 2002
    ..We evaluated the value of anti-Saccharomyces cerevisiae antibodies (ASCA) and perinuclear antineutrophil cytoplasmic antibodies (pANCA) to increase diagnostic accuracy in categorizing IC...
  52. ncbi request reprint Outcome of pregnancy in women with inflammatory bowel disease treated with antitumor necrosis factor therapy
    Fabian Schnitzler
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 17:1846-54. 2011
    ..Infliximab (IFX) and adalimumab (ADA) are attractive treatment options in patients with inflammatory bowel disease (IBD) also during pregnancy but there is still limited data on the benefit/risk profile of IFX and ADA during pregnancy...
  53. doi request reprint Familial aggregation and antimicrobial response dose-dependently affect the risk for Crohn's disease
    Marie Joossens
    Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 16:58-67. 2010
    ..Our aim was to test whether a combination of CD-associated genes involved in innate immunity and/or antibody responses to microbial antigens may be valuable in identifying healthy relatives at risk...
  54. ncbi request reprint Mucosal healing and anti TNFs in IBD
    Gert Van Assche
    Department of Gastroenterology, Leuven University Hospitals, 49 Herestraat, Leuven, Belgium
    Curr Drug Targets 11:227-33. 2010
    ..In clinical practice assessing mucosal healing should be considered in patients with persistent symptoms despite adequate therapy and when treatment discontinuation is being considered...
  55. doi request reprint Seroreactivity against glycolytic enzymes in inflammatory bowel disease
    Nathalie Vermeulen
    Department of Internal Medicine, University Hospitals Leuven, Leuven, Belgium
    Inflamm Bowel Dis 17:557-64. 2011
    ..Patients with inflammatory bowel disease (IBD) carry autoantibodies such as perinuclear antineutrophil cytoplasmic antibodies. The aim of the current study was to further characterize the immune reactivity in IBD...
  56. ncbi request reprint Tumor necrosis factor receptor gene polymorphisms in Crohn's disease: association with clinical phenotypes
    Kevin A Waschke
    Department of Medicine, Division of Gastroenterology, McGill University Inflammatory Bowel Disease Program, Montreal, Canada
    Am J Gastroenterol 100:1126-33. 2005
    ..Our purpose was to determine whether single nucleotide polymorphisms (SNPs) in the TNF receptors confer susceptibility to Crohn's disease and whether they are associated with clinical phenotype...
  57. ncbi request reprint Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial
    Paul Rutgeerts
    Department of Gastroenterology, University Hospital Gasthuisberg, 3000 Leuven, Belgium
    Gastroenterology 128:856-61. 2005
    ..We investigated the efficacy and safety of ornidazole, a nitroimidazole antibiotic, for the prevention of clinical recurrence of Crohn's disease after curative ileocolonic resection in a placebo-controlled double-blind clinical trial...
  58. doi request reprint Reciprocal changes of Foxp3 expression in blood and intestinal mucosa in IBD patients responding to infliximab
    Zhe Li
    Laboratory of Experimental Immunology, Catholic University of Leuven, Leuven, Belgium
    Inflamm Bowel Dis 16:1299-310. 2010
    ..Therefore, we investigated the effect of infliximab (IFX) therapy on Forkhead box protein3 (Foxp3) T cells in blood and intestinal mucosa from Crohn's disease (CD) and ulcerative colitis (UC)...
  59. ncbi request reprint Genetic risk profiling and prediction of disease course in Crohn's disease patients
    Liesbet Henckaerts
    Department of Medicine, Gastroenterology Section, Catholic University of Leuven, Leuven, Belgium
    Clin Gastroenterol Hepatol 7:972-980.e2. 2009
    ..We examined the influence of recently discovered CD-associated susceptibility loci on changes in disease behavior and evaluated whether a genetic risk model for disease progression could be generated...
  60. ncbi request reprint Genetic factors conferring an increased susceptibility to develop Crohn's disease also influence disease phenotype: results from the IBDchip European Project
    Isabelle Cleynen
    Department of Clinical and Experimental Medicine, KU Leuven, Leuven, Belgium
    Gut 62:1556-65. 2013
    ..We aimed to investigate the influence of CD-SNPs and basic patient characteristics on CD clinical course, and develop statistical models to predict CD clinical course...
  61. ncbi request reprint NOD2/CARD15 does not influence response to infliximab in Crohn's disease
    Severine Vermeire
    Department of Gastroenterology, UZ Gasthuisberg, Leuven, Belgium
    Gastroenterology 123:106-11. 2002
    ..It is not clear which factors influence treatment outcome. We assessed whether variants in NOD2/CARD15 are predictive for differences in clinical response...
  62. pmc Interleukin-15 receptor α expression in inflammatory bowel disease patients before and after normalization of inflammation with infliximab
    Clémentine Perrier
    Department of Gastroenterology, Translational Research Centre for Gastrointestinal Disorders TARGID, KU Leuven, Leuven, Belgium
    Immunology 138:47-56. 2013
    ..Expression is localized in B cells, suggesting that IL-15 regulates B-cell functions during bowel inflammation. No change in release of sIL-15Rα is observed in patients treated with IFX...
  63. doi request reprint Tolerability of shortened infliximab infusion times in patients with inflammatory bowel diseases: a single-center cohort study
    Christine Breynaert
    Division of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Am J Gastroenterol 106:778-85. 2011
    ..The primary end point was the incidence of infusion reactions in both groups...
  64. ncbi request reprint Genomic copy number determines functional expression of {beta}-defensin 2 in airway epithelial cells and associates with chronic obstructive pulmonary disease
    Wim Janssens
    Department of Human Genetics, Katholieke Universiteit Leuven, Gasthuisberg O and N1 602, Herestraat 49, B 3000, Leuven, Belgium
    Am J Respir Crit Care Med 182:163-9. 2010
    ..Controversy still exists on whether the beta-defensins genes determine susceptibility for chronic obstructive pulmonary disease (COPD)...
  65. doi request reprint Dysbiosis of the faecal microbiota in patients with Crohn's disease and their unaffected relatives
    Marie Joossens
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Gut 60:631-7. 2011
    ..Whether dysbiosis is present in relatives of patients CD was also examined...
  66. ncbi request reprint Predictive model for the outcome of infliximab therapy in Crohn's disease based on apoptotic pharmacogenetic index and clinical predictors
    Tibor Hlavaty
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 13:372-9. 2007
    ..Predictors of response could improve selection of patients with a higher probability of favorable outcomes and could improve the safety profile. We aimed to develop a predictive model for the response to infliximab in CD...
  67. ncbi request reprint Autoimmunity associated with anti-tumor necrosis factor alpha treatment in Crohn's disease: a prospective cohort study
    Severine Vermeire
    Gastroenterology Department, University Hospital Gasthiuisberg, Leuven, Belgium
    Gastroenterology 125:32-9. 2003
    ..We investigated the occurrence of antinuclear antibodies in 125 consecutive Crohn's disease patients and studied the relationship with symptoms of autoimmunity...
  68. ncbi request reprint Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial
    Geert R D'Haens
    Department of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gastroenterology 135:1123-9. 2008
    ..More than 80% of Crohn's disease (CD) patients undergoing resection suffer recurrence of their disease. Therapy with aminosalicylates, antimetabolites, or antibiotics leads to a modest reduction in the incidence of recurrence...
  69. ncbi request reprint Incidence of colectomy during long-term follow-up after cyclosporine-induced remission of severe ulcerative colitis
    David N Moskovitz
    Department of Internal Medicine, University Hospital, Gasthuisberg Herestraat, Leuven, Belgium
    Clin Gastroenterol Hepatol 4:760-5. 2006
    ..Cyclosporine (CSA) has been shown to be effective in steroid-refractory ulcerative colitis (UC) and as an alternative to glucocorticosteroids in patients with severe attacks of UC. Our aim was to investigate the long-term efficacy of CSA...
  70. ncbi request reprint Small bowel review: Diseases of the small intestine
    Alan B R Thomson
    Nutrition and Metabolism Group, Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Dig Dis Sci 48:1582-99. 2003
  71. ncbi request reprint Predictors of early response to infliximab in patients with ulcerative colitis
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 13:123-8. 2007
    ..Our objective is to report the outcome of infliximab (IFX) in ulcerative colitis (UC) patients from a single center and to identify predictors of early clinical response...
  72. ncbi request reprint Outcome after proctocolectomy with ileal pouch-anal anastomosis for ulcerative colitis
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 14:20-8. 2008
    ..During the course of their disease, about 30% of patients with ulcerative colitis (UC) will undergo proctocolectomy with ileal pouch-anal anastomosis (IPAA). We evaluated the outcome of IPAA in a Belgian referral center...
  73. ncbi request reprint Long-term outcome after infliximab for refractory ulcerative colitis
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B 3000 Leuven, Belgium
    J Crohns Colitis 2:219-25. 2008
    ..We investigated long-term outcome including colectomy rates in outpatients treated with IFX for refractory UC in a single referral centre, and evaluated if predictors could be identified...
  74. ncbi request reprint Influence of immunogenicity on the long-term efficacy of infliximab in Crohn's disease
    Filip Baert
    Department of Internal Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    N Engl J Med 348:601-8. 2003
    ..We evaluated the clinical significance of these antibodies in patients with Crohn's disease...
  75. ncbi request reprint Optimizing anti-TNF treatment in inflammatory bowel disease
    Paul Rutgeerts
    Department of Medicine, Division of Gastroenterology, University of Leuven, Belgium
    Gastroenterology 126:1593-610. 2004
    ..Other adverse events associated with anti-TNF strategies are demyelinating disease and worsening of congestive heart failure. Malignancy rates in patients treated with anti-TNF strategies do not seem to be increased...
  76. ncbi request reprint Optimizing biologic therapies for inflammatory bowel disease (ulcerative colitis and Crohn's disease)
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Curr Gastroenterol Rep 11:504-8. 2009
    ..Finally, it remains unclear if and when a biologic agent can be stopped in patients with long-standing remission...
  77. ncbi request reprint Evaluation of short-term responsiveness and cutoff values of inflammatory bowel disease questionnaire in Crohn's disease
    Tibor Hlavaty
    University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:199-204. 2006
    ..Whereas the validity and reproducibility of the IBDQ have been extensively studied, there are limited data on its short-term responsiveness and cutoff values for remission and partial clinical response...
  78. ncbi request reprint Pharmacogenetics in inflammatory bowel disease
    Marie Pierik
    Department of Gastro enterology, University of Hospital Gasthuisberg, Leuven, Belgium
    World J Gastroenterol 12:3657-67. 2006
    ..An effort should be made to collect genomic DNA from all patients enrolled in clinical drug trials after appropriate informed consent for pharmacogenetic studies...
  79. ncbi request reprint Development of pouchitis following ileal pouch-anal anastomosis (IPAA) for ulcerative colitis: A role for serological markers and microbial pattern recognition receptor genes
    Marc Ferrante
    Department of Gastroenterology, University Hospital Gasthuisberg, Herestraat 49, B3000 Leuven, Belgium
    J Crohns Colitis 2:142-51. 2008
    ..We investigated the role of antimicrobial and antiglycan antibodies and polymorphisms in microbial pattern recognition receptor genes...
  80. ncbi request reprint Anti-alpha-enolase antibodies in patients with inflammatory Bowel disease
    Nathalie Vermeulen
    Department of Internal Medicine, University Hospital Leuven, Leuven, Belgium
    Clin Chem 54:534-41. 2008
    ..alpha-Enolase has been proposed as a target antigen in IBD. We evaluated the prevalence and diagnostic value of anti-alpha-enolase antibodies in IBD and related disorders...
  81. ncbi request reprint Immunogenicity of infliximab: how to handle the problem?
    Filip Baert
    Department of Gastroenterology, University Hospital Leuven, Herestraat 49, 3000 Leuven, Belgium
    Acta Gastroenterol Belg 70:163-70. 2007
    ..Antibody formation is associated with allergic reactions and loss of response...
  82. pmc Mucosal healing in inflammatory bowel disease: impossible ideal or therapeutic target?
    Paul Rutgeerts
    University Hospital Gasthuisberg, Department of Gastroenterology, Herestraat 49, Leuven 3052, Belgium
    Gut 56:453-5. 2007
    ..We propose that future studies should focus on healing and disease course as primary outcome measures...
  83. ncbi request reprint Novel biological strategies in inflammatory bowel diseases
    Severine Vermeire
    Department of Medicine, Division of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 10:S44-51. 2004
  84. ncbi request reprint The role of genetics in inflammatory bowel disease
    Liesbet Henckaerts
    Department of Gastroenterology University Hospital Gasthuisberg, Leuven, Belgium
    Curr Drug Targets 9:361-8. 2008
    ..The optimal prediction of both disease behaviour and response to therapy might result from complex combinations of clinical, biochemical, serological and genetic factors...
  85. ncbi request reprint Crohn's disease and month of birth
    Marc Van Ranst
    Laboratory of Clinical and Epidemiological Virology, Department of Microbiology and Immunology, Rega Institute for Medical Research, University of Leuven, Leuven, Belgium
    Inflamm Bowel Dis 11:597-9. 2005
    ..Some studies suggested an association between the month of birth and the later development of IBD. We studied this putative relationship in a large cohort of Belgian patients with Crohn's disease (CD)...
  86. doi request reprint Management of acute severe ulcerative colitis
    Gert Van Assche
    Division of Gastroenterology, Leuven University Hospitals, Leuven, Belgium
    Gut 60:130-3. 2011
    ..Whereas prolonged exposure to steroids predisposes to an increased rate of peri-operative complications it is still debated whether cyclosporine or infliximab increase peri-operative morbidity in ulcerative colitis...
  87. ncbi request reprint Emerging biological treatments in inflammatory bowel diseases
    Gert Van Assche
    Division of Gastroenterology, University of Leuven, Leuven, Belgium
    Dig Dis 24:131-6. 2006
    ..As illustrated by unexpected but devastating brain infections with anti-adhesion molecules, clinicians should be aware that the powerful immunomodulatory capacity of biologicals necessitates a rigorous safety follow-up...
  88. ncbi request reprint Safety issues with biological therapies for inflammatory bowel disease
    Gert Van Assche
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Curr Opin Gastroenterol 22:370-6. 2006
    ..The purpose of this review is to summarize recent evidence describing specific complications associated with the use of biological therapy derived from controlled trials and from post-marketing surveillance...
  89. ncbi request reprint The impact of uridine diphosphate-glucuronosyltransferase 1A9 (UGT1A9) gene promoter region single-nucleotide polymorphisms T-275A and C-2152T on early mycophenolic acid dose-interval exposure in de novo renal allograft recipients
    Dirk R J Kuypers
    Department of Nephrology and Renal Transplantation, Laboratory of Absorption and Digestion, University Hospitals Leuven, Belgium
    Clin Pharmacol Ther 78:351-61. 2005
    ....
  90. ncbi request reprint Randomized, double-blind comparison of 4 mg/kg versus 2 mg/kg intravenous cyclosporine in severe ulcerative colitis
    Gert Van Assche
    Department of Gastroenterology, University of Leuven, 49, Herestraat, Leuven 3000, Belgium
    Gastroenterology 125:1025-31. 2003
    ..Our single center, randomized, double-blind, controlled trial aimed to evaluate the additional clinical benefit of 4 mg/kg over 2 mg/kg IV cyclosporine in the acute treatment of severe UC...
  91. doi request reprint Biological therapies for inflammatory bowel diseases
    Paul Rutgeerts
    Division of Gastroenterology, University of Leuven Hospitals, Leuven, Belgium
    Gastroenterology 136:1182-97. 2009
    ..The efficacy of each therapy must be shown in carefully designed clinical programs. Biological therapies carry a definite safety risk, so their place in treatment algorithms must be defined carefully...
  92. doi request reprint The potential for disease modification in Crohn's disease
    G Van Assche
    Department of Gastroenterology, University Hospital Leuven, 3000 Leuven, Belgium
    Nat Rev Gastroenterol Hepatol 7:79-85. 2010
    ....
  93. ncbi request reprint Medical treatment of inflammatory bowel diseases
    Gert Van Assche
    Division of Gastroenterology, University of Leuven, Leuven, Belgium
    Curr Opin Gastroenterol 21:443-7. 2005
    ..Despite the advent of the anti-TNF agent, infliximab, an important unmet medical need characterizes the medical treatment of inflammatory bowel diseases. This review aims to summarize recent progress in the field...
  94. ncbi request reprint CC-type chemokine receptor 5-Delta32 mutation protects against primary sclerosing cholangitis
    Liesbet Henckaerts
    Department of Gastroenterology, University Hospital Gasthuisberg, Leuven, Belgium
    Inflamm Bowel Dis 12:272-7. 2006
    ..We therefore investigated the role of the functional 32-bp deletion in this gene (CCR5-Delta32) with regard to susceptibility to PSC...
  95. ncbi request reprint Optimizing treatment of inflammatory bowel diseases with biologic agents
    Gert Van Assche
    Division of Gastroenterology, University of Leuven, 49, Herestraat 3000 Leuven, Belgium
    Curr Gastroenterol Rep 10:591-6. 2008
    ....
  96. doi request reprint Polymorphisms in innate immunity genes predispose to bacteremia and death in the medical intensive care unit
    Liesbet Henckaerts
    Department of Medicine, Catholic University of Leuven, Leuven, Belgium
    Crit Care Med 37:192-201, e1-3. 2009
    ..Our aim was to study the influence of single nucleotide polymorphisms in selected genes involved in innate immunity on the development of bacteremia or risk of death in patients admitted to a medical intensive care unit...
  97. ncbi request reprint Contribution of genetic and environmental factors in the pathogenesis of Crohn's disease in a large family with multiple cases
    Marie Joossens
    Department of Gastroenterology, University Hospital, Leuven, Belgium
    Inflamm Bowel Dis 13:580-4. 2007
    ..In this family the father developed Crohn's disease (CD) after moving from Morocco to Belgium and successively 4 of his 8 children subsequently developed CD. There was no previous history of familial CD...
  98. ncbi request reprint Interassay and interobserver variability in the detection of anti-neutrophil cytoplasmic antibodies in patients with ulcerative colitis
    Sofie Joossens
    Department of Gastroenterology, University Hospital Gasthuisberg, KULeuven, Leuven, Belgium
    Clin Chem 50:1422-5. 2004
  99. ncbi request reprint Toll-like receptor 2 and Toll-like receptor 4 polymorphisms in invasive pneumococcal disease
    Leen Moens
    Department of Laboratory Medicine, University Hospital Leuven, Centraal Dienstengebouw, Herestraat 49, B 3000 Leuven, Belgium
    Microbes Infect 9:15-20. 2007
    ..Studies have revealed associations between polymorphisms in TLRs and human diseases. The effect of polymorphisms in TLR2 and TLR4 in the human defense to S. pneumoniae has not been studied...
  100. ncbi request reprint Small bowel review: Normal physiology, part 2
    Alan B R Thomson
    Nutrition and Metabolism Group, Division of Gastroenterology, Department of Medicine, University of Alberta, Edmonton, Alberta, Canada
    Dig Dis Sci 48:1565-81. 2003